Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]